SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Wendy J. Komocsar, Jamie L. Blackbourne, Carolyn A. Halstead, Colleen J. Winstead, Daniel Wierda, Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations, Journal of Immunotoxicology, 2015, 1

    CrossRef

  2. 2
    Maria Greenwald, Leszek Szczepanski, Alastair Kennedy, Melissa Veenhuizen, Wendy J Komocsar, Emery Polasek, Kelly Guerrettaz, Pierre-Yves Berclaz, Chin Lee, A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell–activating factor monoclonal antibody, for rheumatoid arthritis, Arthritis Research & Therapy, 2014, 16, 4, 1

    CrossRef

  3. 3
    Paul K. Owens, Eyas Raddad, Jeffrey W. Miller, John R. Stille, Kenneth G. Olovich, Neil V. Smith, Rosie S. Jones, Joel C. Scherer, A decade of innovation in pharmaceutical R&D: the Chorus model, Nature Reviews Drug Discovery, 2014, 14, 1, 17

    CrossRef

  4. 4
    Ignazio Olivieri, Salvatore D'Angelo, Carlo Palazzi, Angela Padula, Advances in the management of psoriatic arthritis, Nature Reviews Rheumatology, 2014, 10, 9, 531

    CrossRef

  5. 5
    Christophe Richez, Marie-Elise Truchetet, Thierry Schaeverbeke, Bernard Bannwarth, Atacicept as an investigated therapy for rheumatoid arthritis, Expert Opinion on Investigational Drugs, 2014, 23, 9, 1285

    CrossRef

  6. 6
    Homa Timlin, Clifton O Bingham, Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis, Expert Opinion on Biological Therapy, 2014, 14, 7, 893

    CrossRef

  7. 7
    Chi Chiu Mok, Emerging biological therapies for systemic lupus erythematosus, Expert Opinion on Emerging Drugs, 2014, 19, 2, 303

    CrossRef

  8. 8
    Gary Reynolds, Faye AH Cooles, John D Isaacs, Catharien MU Hilkens, Emerging immunotherapies for rheumatoid arthritis, Human Vaccines & Immunotherapeutics, 2014, 10, 4, 822

    CrossRef

  9. 9
    Barry J Sheane, Vinod Chandran, Investigational drugs for treating psoriatic arthritis, Expert Opinion on Investigational Drugs, 2014, 23, 7, 1001

    CrossRef

  10. 10
    Lara Valor, Francisco Javier López-Longo, Modulación del sistema de supervivencia y maduración del linfocito B: presente y futuro de una nueva estrategia terapéutica en el lupus eritematoso sistémico, Medicina Clínica, 2014,

    CrossRef

  11. 11
    Carlo Selmi, Elena Generali, Marco Massarotti, Gerolamo Bianchi, Carlo A. Sciré, New treatments for inflammatory rheumatic disease, Immunologic Research, 2014, 60, 2-3, 277

    CrossRef

  12. 12
    Benjamin Knier, Bernhard Hemmer, Thomas Korn, Novel monoclonal antibodies for therapy of multiple sclerosis, Expert Opinion on Biological Therapy, 2014, 14, 4, 503

    CrossRef

  13. 13
    Zozik Fattah, David A Isenberg, Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies, Expert Opinion on Biological Therapy, 2014, 14, 3, 311

    CrossRef

  14. 14
    Yves Troyanov, Ira N Targoff, Marie-Pier Payette, Jean-Pierre Raynauld, Suzanne Chartier, Jean-Richard Goulet, Josiane Bourré-Tessier, Eric Rich, Tamara Grodzicky, Marvin J. Fritzler, France Joyal, Martial Koenig, Jean-Luc Senécal, Redefining Dermatomyositis, Medicine, 2014, 93, 24, 296

    CrossRef

  15. 15
    Shu Yang, Jian-Yong Li, Wei Xu, Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma, Critical Reviews in Oncology/Hematology, 2014, 91, 2, 113

    CrossRef

  16. 16
    Ian C. Scott, David L. Scott, Spleen Tyrosine Kinase Inhibitors for Rheumatoid Arthritis: Where Are We Now?, Drugs, 2014, 74, 4, 415

    CrossRef

  17. 17
    Morton A Scheinberg, Dinesh Srinivasan, Renee S Martin, The potential role of blisibimod for the treatment of systemic lupus erythematosus, International Journal of Clinical Rheumatology, 2014, 9, 2, 121

    CrossRef

  18. 18
    Amina A. Mahdy, Hala A. Raafat, Hussein S. El-Fishawy, Tamer A. Gheita, Therapeutic potential of hydroxychloroquine on serum B-cell activating factor belonging to the tumor necrosis factor family (BAFF) in rheumatoid arthritis patients, Bulletin of Faculty of Pharmacy, Cairo University, 2014, 52, 1, 37

    CrossRef

  19. 19
    Chi Chiu Mok, Update on B-cell targeted therapies for systemic lupus erythematosus, Expert Opinion on Biological Therapy, 2014, 14, 6, 773

    CrossRef

  20. 20
    Manu Chhabra, Thomas M. Conlon, Kourosh Saeb-Parsy, Gavin J. Pettigrew, BAFF and Associated TNF Superfamily Members in Renal Transplantation, Transplantation Journal, 2013, 96, 10, 853

    CrossRef

  21. 21
    Ronald F. van Vollenhoven, Ioannis Parodis, Adrian Levitsky, Biologics in SLE: Towards new approaches, Best Practice & Research Clinical Rheumatology, 2013, 27, 3, 341

    CrossRef

  22. 22
    Florian MP Meier, Marc Frerix, Walter Hermann, Ulf Müller-Ladner, Current immunotherapy in rheumatoid arthritis, Immunotherapy, 2013, 5, 9, 955

    CrossRef

  23. 23
    William Stohl, Future prospects in biologic therapy for systemic lupus erythematosus, Nature Reviews Rheumatology, 2013, 9, 12, 705

    CrossRef

  24. 24
    Marc Cohen, Mohammed A Omair, Edward C Keystone, Monoclonal antibodies in rheumatoid arthritis, International Journal of Clinical Rheumatology, 2013, 8, 5, 541

    CrossRef

  25. 25
    Fabien B. Vincent, Damien Saulep-Easton, William A. Figgett, Kirsten A. Fairfax, Fabienne Mackay, The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity, Cytokine & Growth Factor Reviews, 2013, 24, 3, 203

    CrossRef

  26. 26
    Andrew Filer, The fibroblast as a therapeutic target in rheumatoid arthritis, Current Opinion in Pharmacology, 2013, 13, 3, 413

    CrossRef

  27. 27
    Divi Cornec, Alain Saraux, Valérie Devauchelle-Pensec, Coralie Clodic, Jacques-Olivier Pers, The future of B cell-targeted therapies in Sjögren’s syndrome, Immunotherapy, 2013, 5, 6, 639

    CrossRef

  28. 28
    Penelope Ward, Mark Bodmer, Antibodies in Phase III Studies for Immunological Disorders,
  29. 29
    Frank R. Brennan, B-Cell Inhibitors in Phase 1 and 2 Clinical Studies for Immunological Disorders,